Literature DB >> 32631604

Risk Factors and Cancer Screening in Myositis.

Siamak Moghadam-Kia1, Chester V Oddis2, Dana P Ascherman3, Rohit Aggarwal4.   

Abstract

The idiopathic inflammatory myopathies, particularly dermatomyositis, are associated with an increased risk of cancer. Lung, ovarian, breast, colon, prostate, and cervical cancers, and hematologic malignancies, are among the most common associated cancers. Risk stratification for cancer in patients with myositis is based on clinical risk factors/red flags, myositis clinical subtypes, and myositis-specific autoantibodies. Clinical risk factors include older age at disease onset, male gender, dysphagia, acute onset/refractory myositis, cutaneous ulceration, necrosis/vasculitis, and elevated inflammatory markers. Appropriate screening strategies are based on the risk level. Further studies are warranted to determine the role of advanced imaging and comprehensive cancer screening.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer screening; Dermatomyositis; Idiopathic inflammatory myopathies

Year:  2020        PMID: 32631604     DOI: 10.1016/j.rdc.2020.05.006

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  9 in total

Review 1.  Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis.

Authors:  David F Fiorentino; Livia Casciola-Rosen
Journal:  Clin Rev Allergy Immunol       Date:  2022-05-20       Impact factor: 8.667

Review 2.  Paraneoplastic musculoskeletal disorders: review and update for radiologists.

Authors:  Kimia Khalatbari Kani; Jack A Porrino; Michael E Mulligan; Felix S Chew
Journal:  Skeletal Radiol       Date:  2022-05-23       Impact factor: 2.199

3.  Long-term risks of malignancy in myositis-specific antibody-positive idiopathic inflammatory myopathy.

Authors:  Shinji Izuka; Toshihiko Komai; Hirofumi Shoda; Keishi Fujio
Journal:  Rheumatol Int       Date:  2022-09-29       Impact factor: 3.580

4.  Machine Learning Algorithms Identify Clinical Subtypes and Cancer in Anti-TIF1γ+ Myositis: A Longitudinal Study of 87 Patients.

Authors:  Lijuan Zhao; Shuoshan Xie; Bin Zhou; Chuyu Shen; Liya Li; Weiwei Pi; Zhen Gong; Jing Zhao; Qi Peng; Junyu Zhou; Jiaqi Peng; Yan Zhou; Lingxiao Zou; Liang Song; Honglin Zhu; Hui Luo
Journal:  Front Immunol       Date:  2022-02-14       Impact factor: 7.561

Review 5.  Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis.

Authors:  Milena Marzęcka; Anna Niemczyk; Lidia Rudnicka
Journal:  Clin Rev Allergy Immunol       Date:  2022-02-11       Impact factor: 10.817

6.  A case of recurrent and paraneoplastic pityriasis rubra pilaris.

Authors:  Olivia Lamberg; Severine Cao; Stephanie Sabater-Geib; Lori Lowe; James Elder
Journal:  JAAD Case Rep       Date:  2021-04-29

7.  A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies.

Authors:  Alexander G S Oldroyd; Andrew B Allard; Jeffrey P Callen; Hector Chinoy; Lorinda Chung; David Fiorentino; Michael D George; Patrick Gordon; Kate Kolstad; Drew J B Kurtzman; Pedro M Machado; Neil J McHugh; Anna Postolova; Albert Selva-O'Callaghan; Jens Schmidt; Sarah Tansley; Ruth Ann Vleugels; Victoria P Werth; Rohit Aggarwal
Journal:  Rheumatology (Oxford)       Date:  2021-06-18       Impact factor: 7.580

Review 8.  Update on Malignancy in Myositis-Well-Established Association with Unmet Needs.

Authors:  Aleksandra H Opinc; Joanna S Makowska
Journal:  Biomolecules       Date:  2022-01-11

9.  Using autoantibody signatures to define cancer risk in dermatomyositis.

Authors:  Jessica L Turnier; J Michelle Kahlenberg
Journal:  J Clin Invest       Date:  2022-01-18       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.